Immunotherapy versus chemotherapy as first-line treatment for advanced urothelial cancer: A systematic review and meta-analysis

Alberto Martini(The University of Texas MD Anderson Cancer Center), Andrea Necchi(Vita-Salute San Raffaele University), Alberto Briganti(University College London Hospitals NHS Foundation Trust), Luigi Nocera(Istituti di Ricovero e Cura a Carattere Scientifico), Andrea Salonia(Vita-Salute San Raffaele University), Daniele Raggi(Fondazione IRCCS Istituto Nazionale dei Tumori), Francesco Montorsi(Vita-Salute San Raffaele University), Giuseppe Fallara(Istituti di Ricovero e Cura a Carattere Scientifico), Julianne G. Schultz(National Institutes of Health), Laura Marandino, Thomas Powles(Queen Mary University of London), Federico Belladelli(IRCCS Ospedale San Raffaele)
Cancer Treatment Reviews
February 9, 2022
10.1016/j.ctrv.2022.102360
Cited by 34

Related Papers

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|3.7k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
|Nature|2014|2.4k
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
|The Lancet Oncology|2017|1.8k